We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+31.06%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$4.93B
AUM Growth
+$243M
Cap. Flow
-$263M
Cap. Flow %
-5.34%
Top 10 Hldgs %
50.68%
Holding
90
New
9
Increased
18
Reduced
10
Closed
20

Top Buys

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$113M
2
ACRV icon
Acrivon Therapeutics
ACRV
+$61.1M
3
VOR icon
Vor Biopharma
VOR
+$57.5M
4
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$53.5M
5
PCVX icon
Vaxcyte
PCVX
+$50.1M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$180M
2
BIIB icon
Biogen
BIIB
+$114M
3
RLMD icon
Relmada Therapeutics
RLMD
+$74M
4
ASND icon
Ascendis Pharma A/S
ASND
+$70.9M
5
THRD
Third Harmonic Bio
THRD
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.6B
$850M 17.23%
6,957,179
-610,721
-8% -$70.9M
PCVX icon
2
Vaxcyte
PCVX
$7.61B
$281M 5.7%
5,857,459
+1,276,256
+28% +$50.1M
JBIO
3
Jade Biosciences
JBIO
$1.18B
$242M 4.91%
236,114
– –
DICE
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$214M 4.33%
6,848,911
+1,640,000
+31% +$53.5M
VRNA
5
DELISTED
Verona Pharma
VRNA
$165M 3.35%
6,317,990
+267,990
+4% +$3.57M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.29B
$161M 3.26%
5,516,067
+45,000
+0.8% +$1.16M
DAWN
7
DELISTED
Day One Biopharmaceuticals
DAWN
$152M 3.07%
7,040,622
– –
VOR icon
8
Vor Biopharma
VOR
$1.06B
$151M 3.07%
1,137,444
+581,395
+105% +$57.5M
BIIB icon
9
Biogen
BIIB
$31B
$148M 2.99%
532,892
-404,657
-43% -$114M
CTKB icon
10
Cytek Biosciences
CTKB
$562M
$137M 2.77%
13,381,054
– –
LEGN icon
11
Legend Biotech
LEGN
$3.65B
$122M 2.47%
2,436,223
+97,613
+4% +$4.73M
RNAM
12
DELISTED
Avidity Biosciences
RNAM
$121M 2.45%
5,454,533
+3,287,142
+152% +$49M
WVE icon
13
Wave Life Sciences
WVE
$1.12B
$120M 2.44%
17,202,009
– –
JANX icon
14
Janux Therapeutics
JANX
$911M
$114M 2.32%
8,670,644
– –
ETNB
15
DELISTED
89bio
ETNB
$114M 2.31%
8,955,410
+1,172,741
+15% +$10.6M
PEPG icon
16
PepGen
PEPG
$118M
$109M 2.21%
8,131,952
– –
IMGN
17
DELISTED
Immunogen Inc
IMGN
$108M 2.2%
21,853,958
+112,500
+0.5% +$610K
BLU
18
DELISTED
BELLUS Health Inc.
BLU
$102M 2.08%
12,452,574
+1,067,000
+9% +$9.95M
INBX
19
DELISTED
Inhibrx, Inc. Common Stock
INBX
$95M 1.93%
+3,853,867
New +$113M
CLDX icon
20
Celldex Therapeutics
CLDX
$2.94B
$92.5M 1.88%
2,075,000
– –
ITOS
21
DELISTED
iTeos Therapeutics
ITOS
$86.3M 1.75%
4,417,259
– –
TVTX icon
22
Travere Therapeutics
TVTX
$5.18B
$83.8M 1.7%
3,984,681
-938,260
-19% -$19.9M
COGT icon
23
Cogent Biosciences
COGT
$6.76B
$69.4M 1.41%
5,999,481
+1,986,028
+49% +$24.6M
ACRS icon
24
Aclaris Therapeutics
ACRS
$715M
$69.3M 1.41%
4,398,453
– –
FULC icon
25
Fulcrum Therapeutics
FULC
$240M
$69.2M 1.4%
9,505,925
+2,505,925
+36% +$16.3M
1
2 3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, RA Capital Management held 90 positions worth $4.93B, up 5.2% from $4.69B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management withdrew a net $263M in Q4 2022, closing 20 positions and reducing 10 holdings. Its most notable exit was Forma Therapeutics Holdings, Inc. Common Stock, an estimated $180M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, RA Capital Management opened a new position in Inhibrx, Inc. Common Stock worth $95M.

  • RA Capital Management's largest Q4 2022 buy was Inhibrx, Inc. Common Stock: 3,853,867 shares worth $95M.
  • RA Capital Management added most to Vor Biopharma in Q4 2022, an estimated $57.5M increase.
  • RA Capital Management's biggest Q4 2022 reduction was Biogen, cutting an estimated $114M.
  • RA Capital Management fully exited Forma Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $180M.
  • RA Capital Management's ten largest holdings make up 51% of its $4.93B portfolio in Q4 2022.
  • RA Capital Management opened 9 new positions and closed 20 in Q4 2022.
  • RA Capital Management's portfolio value rose 5.2% quarter-over-quarter to $4.93B.

Based on RA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.